EndeavorRx® Prospective Product Registry ("Expedition EndeavorRx")

ADHD Clinical Trial

Official title: EndeavorRx® Prospective Product Registry

Status Enrolling by invitation

Clinical Trial Summary

The EndeavorRx Prospective Product Registry aims to collect real world data from participants receiving the digital therapeutic, EndeavorRx, under conditions of routine clinical practice.

Clinical Trial Description

The objectives of this registry are to describe clinical and demographic characteristics, prescribing patterns, treatment patterns, and outcomes in participants treated with EndeavorRx in a real-world setting. Patients and their caregivers will be informed about the registry as part of a series of product welcome emails following product activation. Patients/caregivers enroll into the study by providing their electronic informed consent (eConsent) and assent (eAssent). All data are captured electronically and securely through a commercial data capture platform. Participants can also invite their child's teacher to submit surveys of their observations of the child's ADHD symptoms for the study. Study activities are emailed to caregivers at baseline, 1, 2, 3, and 6-months after enrollment. A valid and active EndeavorRx prescription is required to enroll. However, an active prescription throughout the entire 6 months of study participation is not required. ;

Related Conditions & MeSH terms

• ADHD

• NCT number: NCT05991167
• Study type: Observational [Patient Registry]
• Source: Akili Interactive Labs, Inc.
• Status: Enrolling by invitation
• Start date: June 1, 2022
• Completion date: December 31, 2025